Rheumatology

Thoracic Malignancies

Questions discussed in this category

Do you use immune checkpoint inhibitors in NSCLC patients with pre-existing, well-controlled autoimmune disease?

Does the type of autoimmune disease (ex IBD, rheumatoid arthritis, interstitial lung disease) matter?

2 Answers available

What is your approach for an RA patient with lung cancer who is starting immunotherapy?

1 Answer available

Is polymyalgia rheumatica associated with increased toxicity for lung SBRT?

1 Answer available

How would you treat active rheumatoid arthritis in a patient in complete response on loralatinib for stage IV ALK positive NSCLC?

Patient already on methotrexate and plaquenil.

1 Answer available

Are there any risk factors for IO induced rhabdomyolysis and how do you approach and manage it?

2 Answers available

Would you still consider durvalumab consolidation after definitive chemoradiation for patients with Stage III NSCLC who are on stable weekly methotrexate dosing for psoriasis/psoriatic arthritis?

1 Answer available

What are your recommendations for a patient with metastatic non-mutated lung adenocarcinoma who previously had headaches responsive to prednisone but with negative temporal artery biopsy for GCA?

For medical oncologists, would you offer a PD-1/L1 inhibitor? For other subspecialties, how would you counsel the oncologist regarding the risk of usi...

1 Answer available

Would you offer lung SBRT to a medically inoperable patient with systemic lupus erythematosus or other connective tissue disorders if well controlled?

If so, do you take any additional precautions with planning?

1 Answer available

Would you offer lung SBRT for an individual with rheumatoid arthritis?

Also, how would you handle immune modulators for rheumatoid arthritis during their treatment?

1 Answer available

How do you identify immunotherapy-related pneumonitis vs. radiation pneumonitis in a patient status post chemoradiation receiving consolidation immunotherapy?

Is IO related pneumonitis in the radiation field or more diffuse?

1 Answer available

In which patients with stage IV NSCLC and PD-L1 TPS >50% plus concomitant autoimmune disease is it considered safe to give immune checkpoint blockers?

1 Answer available

Papers discussed in this category

Nature reviews. Rheumatology, 2022 Oct 05

Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.

Oncoimmunology, 2023 Oct 30

Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.

JAMA Netw Open, 2021 Feb 01

Assessment of Toxic Effects Associated With Dose-Fractionated Radiotherapy Among Patients With Cancer and Comorbid Collagen Vascular Disease.

Annals of internal medicine, 2018-01-16

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2004

Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-03

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

The New England journal of medicine, 2015-07-16

J Immunother Cancer,

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.

Journal of immunotherapy (Hagerstown, Md. : 1997), 2018-05

PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies.

Neurology, 2019 Mar 08

Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.

Front Immunol, 2022 Aug 22

Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years.

Rheumatology

Thoracic Malignancies

Questions discussed in this category

Papers discussed in this category

Related Topics in Rheumatology